Five, seven or ten? No – it’s not a trendy store for juniors… it is a real-life anti-estrogen treatment dilemma facing oncologists and their post-menopausal, ER+, early-stage, breast cancer patients. Standard of care is to take anti-estrogen treatment for at least the first 5 years after diagnosis to help prevent hormone-receptor positive breast cancer recurrences.
Welcome to the BeWisER+ About Breast Cancer Blog! Our goal is to be a resource for ER+ breast cancer patients and survivors in all aspects of the patient journey. We will provide tips for life after breast cancer, advice on how to navigate conversations with your doctor and share other survivors’ stories. Check back here for biweekly updates. Thanks for being a part of our community!
The world’s best-known breast cancer experts weigh in on issues related to ER+ early stage breast cancer – Part 1
In a consensus report published last week, Endocrine therapy and related issues in hormone receptor‑positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG), the BCTEG addressed four gaps in current guidance for oncologists related to the most common form of breast cancer, estrogen receptor positive (ER+) early stage breast …
Survivorship is one of the biggest buzz words in cancer currently. It turns out that survivorship means different things to different groups of people. See what women who beat breast cancer are saying about their preferences that are in common.
Anti-estrogen therapy is an important part of the treatment for patients with early stage estrogen-receptor-positive breast cancer. These treatments can greatly improve a patient’s odds of beating cancer, but they also can come with difficult side effects and toxicities.
Picking up where we left off In our last blog, we discussed how your aromatase inhibitor (AI) therapy can affect the health of your bones. Hormones within your body help to maintain healthy bone by balancing the processes of bone loss and formation that naturally occur during one’s lifetime.
Did you know that some treatments for estrogen-receptor positive (ER+) breast cancer can cause bone loss? Recently, experts in the field compiled the data and made recommendations about how to handle this growing issue for the ~80% of patients diagnosed with this type of breast cancer. Let’s start with a little background information. First the … Continue reading What’s Up With Bone Loss and Breast Cancer?
This month we attended the 34th Annual Miami Breast Cancer Conference, hosted by the Physicians’ Education Resource (PER). This globally-recognized conference brings together healthcare professionals from all over the world to share and discuss the latest advances in breast cancer management and care. There were many noteworthy discussions at this year’s event. We’ve picked our … Continue reading Our Top Three Highlights from the Miami Breast Cancer Conference
In late January, physicians and advocates of breast cancer survivors attended the 2nd annual Cancer Survivorship Symposium: Advancing Care and Research event in San Diego. The conference, hosted by the American Academy of Family Physicians, the American College of Physicians, and the American Society of Clinical Oncology, aimed to explore topics concerning the needs of … Continue reading The Cancer Survivorship Symposium: A Recap for Breast Cancer Survivors
Knowledge is Power: Three Important Things to Know about Recent Clinical Trials on Extended Aromatase Inhibitor Therapy
Last month at the San Antonio Breast Cancer Symposium (SABCS) the results of three extended anti-estrogen therapy trials were presented that could have a big impact on the standard of care for ER+ breast cancer patients and survivors. You may have heard buzz about the trial results, and what they mean for the ER+ breast … Continue reading Knowledge is Power: Three Important Things to Know about Recent Clinical Trials on Extended Aromatase Inhibitor Therapy
Last week marked another busy and exciting few days at the 2016 San Antonio Breast Cancer Symposium (SABCS), a five-day conference geared toward an international community of more than 7,000 physicians, researchers, and advocates. The purpose of the annual meeting is to share and discuss data and insights from groundbreaking research on breast cancer biology, … Continue reading Highlights from the San Antonio Breast Cancer Symposium (SABCS)
Although there are many ways to celebrate the holidays – from intimate family get-togethers to large gatherings with friends – the holidays are mostly about being together and showing gratitude. But for breast cancer survivors, the holidays can evoke a range of complex emotions. So what’s it like to return home for the holidays, after having breast cancer? … Continue reading The Holidays after Breast Cancer: Five Pieces of Advice from ER+ Breast Cancer Survivors
Some of the most sudden and shocking changes for breast cancer patients are in their physical appearance. These physical changes can have a serious impact on how survivors feel about themselves.
You’ve heard those words “you’re cancer free,” but for the last several years, you’ve been taking anti-estrogen medicine. Although anti-estrogen therapy may help prevent your cancer from returning, the side effects can be a pain, and may be debilitating, draining and even unbearable for some women.
After a Breast Cancer Diagnosis, What Comes Next? What Newly Diagnosed Patients Can Do to Personalize Their Cancer Journey
If you’ve been diagnosed with breast cancer, it’s normal to feel shock, fear, and anxiety. But becoming informed may make it easier to cope with the reality of your diagnosis. Talk to your doctor to better understand your diagnosis so you and your doctor can determine the appropriate treatment path for your individual needs. Here are 3 steps to help you make the best personal decisions during your cancer journey.
Lisa Whitmyer, a nine-year survivor of ER+, early-stage breast cancer and a team leader in the commercial division of Biotheranostics, Inc. spends most of her waking hours educating physicians about Breast Cancer Index, a test that provides information on risk of recurrence and likelihood of benefit from extended anti-estrogen therapy for ER+, early-stage breast cancer patients. Recently, finding limited free time within a consuming professional career, Lisa has been training, and training for an IRONMAN held in Lake Placid, NY just last weekend.
As you enter the survivorship phase of your treatment, you may be wondering about the chances of the cancer returning. The risk of recurrence is different for each breast cancer survivor, and depends on many factors, including the type of breast cancer you were originally diagnosed with.
Congratulations – you finished cancer treatment and received great news from your doctor: you’re in remission. Now it’s time to plan for the coming months and years.
Beyond 5 years? What’s next? 4 Questions to Discuss with Your Doctor About Continuing Anti-Estrogen Therapy
The prognosis for early-stage, estrogen receptor-positive (ER+) breast cancer is generally favorable.
The 2016 American Society of Clinical Oncology (ASCO) Annual Meeting saw more than 30,000 cancer care professionals come together in Chicago for a 5-day event.
Living with a diagnosis of ER+ breast cancer is challenging and takes a significant toll on one’s body and mind. Although stories can be relatable, everyone’s overall experience with cancer is different.
You’ve made it through all the treatments, the surgeries, the hospital visits and you finally heard those magic words: “You’re cancer free.” But now what?